Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases
G Ardissino, S Testa, I Possenti, F Tel… - American Journal of …, 2014 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic
microangiopathy, and as many as 70% of patients with aHUS have mutations in the genes …
microangiopathy, and as many as 70% of patients with aHUS have mutations in the genes …
Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome
KL Wijnsma, C Duineveld, EB Volokhina… - Nephrology Dialysis …, 2018 - academic.oup.com
Background Atypical haemolytic uremic syndrome (aHUS) is a rare but severe form of
thrombotic microangiopathy as a consequence of complement dysregulation. aHUS has a …
thrombotic microangiopathy as a consequence of complement dysregulation. aHUS has a …
[HTML][HTML] Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …
[HTML][HTML] Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial
F Fakhouri, M Hourmant, JM Campistol… - American journal of …, 2016 - Elsevier
Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …
disease of chronic uncontrolled complement activation leading to thrombotic …
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
M Cugno, R Gualtierotti, I Possenti… - … of Thrombosis and …, 2014 - Wiley Online Library
Background Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy
characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that …
characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that …
[HTML][HTML] Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
KL Wijnsma, C Duineveld, JFM Wetzels… - Pediatric …, 2019 - Springer
With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …
[HTML][HTML] Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
Background There are limited long-term outcome data in eculizumab-treated patients with
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …
Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases
F Fakhouri, Y Delmas, F Provot, C Barbet… - American journal of …, 2014 - Elsevier
Background Atypical hemolytic uremic syndrome (aHUS) is a devastating form of renal
thrombotic microangiopathy. Despite plasma exchange, the standard treatment of aHUS for …
thrombotic microangiopathy. Despite plasma exchange, the standard treatment of aHUS for …
Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings
S Tschumi, M Gugger, BS Bucher, M Riedl… - Pediatric …, 2011 - Springer
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated
with defective regulation of the alternative complement pathway. The prognosis for patients …
with defective regulation of the alternative complement pathway. The prognosis for patients …
[HTML][HTML] Atypical hemolytic uremic syndrome (aHUS): treating the patient
J Laurence - Clin Adv Hematol Oncol, 2013 - hematologyandoncology.net
The 3 major thrombotic microangiopathies (TMAs) are thrombotic thrombocytopenic purpura
(TTP), atypical hemolytic uremic syndrome (aHUS), and Shiga toxin–producing Escherichia …
(TTP), atypical hemolytic uremic syndrome (aHUS), and Shiga toxin–producing Escherichia …